Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Upgraded by Zacks Investment Research to Buy

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, October 24th. The brokerage currently has a $18.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 36.88% from the company’s current price.

According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “

A number of other analysts have also weighed in on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Piper Jaffray Companies increased their target price on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Finally, HC Wainwright set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $21.67.

Shares of Vanda Pharmaceuticals (VNDA) opened at $13.15 on Tuesday. Vanda Pharmaceuticals has a 1 year low of $12.60 and a 1 year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). The business had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company’s revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.01) earnings per share. equities analysts expect that Vanda Pharmaceuticals will post -0.42 earnings per share for the current year.

WARNING: “Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Upgraded by Zacks Investment Research to Buy” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/vanda-pharmaceuticals-inc-vnda-upgraded-at-zacks-investment-research-2.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc lifted its holdings in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,022 shares during the period. Kopp Investment Advisors LLC bought a new position in shares of Vanda Pharmaceuticals during the second quarter valued at approximately $196,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Vanda Pharmaceuticals during the third quarter valued at approximately $277,000. American International Group Inc. increased its stake in shares of Vanda Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after purchasing an additional 1,491 shares in the last quarter. Finally, Voya Investment Management LLC increased its stake in shares of Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 4,605 shares in the last quarter. Institutional investors and hedge funds own 87.01% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply